HomeENGLISH MAGAZINETargeting drive-through proteins for docking guests: a new hope for cystic fibrosis

Targeting drive-through proteins for docking guests: a new hope for cystic fibrosis

Cystic fibrosis, one of the most common genetic diseases, causes severe respiratory and digestive disorders. Cystic fibrosis, affecting more than 700,000 people worldwide, is one of the most common genetic diseases and start already in childohood, impairing kids’ life quality. It stems from mutations in the gene responsible for a membrane channel protein that participates in the secretion of mucus, making it abnormally thick. The alteration of this single gene leads to severe respiratory and digestive problems as well, since it is reported that patients may develop diabetes in time. In lungs for example, hyperviscous mucus stagnates and obstructs airways. Despite considerable therapeutic advances, this disease still reduces life expectancy, in particular due to life-threatening respiratory infections. Scientists from the University of Geneva (UNIGE) have discovered the reason for this large number of lung infections: a protein, Vav3, promotes these infections by creating a “bacterial docking station” on airways’ surface. Inhibiting this protein might prevent bacteria from docking on airways’ surface and causing recurrent infections.

These results, to be read in the journal Cell Reports, pave the way of interesting therapeutic prospects for limiting respiratory complications in people with cystic fibrosis. Mucus accumulation does not only obstruct airways, it also promotes persistent lung infections. Despite major therapeutic advances, these lung infections remain frequent and serious. They are mostly due to a bacterium known for its resistance to antibiotics, Pseudomonas aeruginosa. While it is known that mucus viscosity plays a role in trapping bacteria, the reason why they anchor so easily to airways was unknown. However, anchoring of Pseudomonas aeruginosa to airways’ cells is the starting point for these often fatal infections. Understanding this process could help preventing their occurrence. UNIGE researchers compared airway cells from sick people with healthy cells. The whole project began when scientists found that the protein Vav3, which had not been shown to be involved in this disease until now, was over-expressed in sick cells. After numerous in vitro tests, they discovered what this protein does: it really directs (not intentionally though) the construction of an operational bacterial docking station.

In concrete terms, Vav3 forces two other proteins, fibronectin and integrin beta1, to associate with it on cell surface and create a complex that promotes Pseudomonas aeruginosa infections. Professor Marc Chanson, Department of Cell Physiology and Metabolism, Faculty of Medicine, Universite de Geneve, explained: “This is the first time that a mechanism creating a favourable microenvironment for a bacterium before it even arrives has been observed. This might explain the high number of chronic lung infections in people with cystic fibrosis. How to build on this mechanism to develop therapeutic options? By inhibiting Vav3 in sick cells, we succeeded in preventing the expression of the two other proteins that make up the docking station. And, indeed, the absence of this structure limits the adhesion of the bacterium. Although the exact link between the protein Vav3 and the genetic defect that causes cystic fibrosis has yet to be determined, this discovery is a promising therapeutic target for limiting respiratory complications”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Badaoui M et al., Chanson M. Cell Rep. 2020 Jul 7; 32(1):107842.

Rosen BH, Chanson M et al. J Cyst Fibros. 2018; 17(2S):S28-S34. 

Bou Saab J et al. Int J Biochem Cell Biol. 2016 Sep; 78:361-369.

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento enzimaticamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (Leader of the R&D for the partnership CoFood s.r.l.) - Autore di articoli su informazione medica e salute sul sito www.medicomunicare.it (Medical/health information on website) - Autore di corsi ECM FAD pubblicizzati sul sito www.salutesicilia.it
- Advertisment -